Your browser doesn't support javascript.
loading
Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Article em En | IMSEAR | ID: sea-91609
Patients with idiopathic hypereosinophilic syndrome (HES) show persistent hypereosinophilia of unknown etiology that is associated with end-organ damage. Different treatments, including the use of corticosteroids and cytotoxics, have been investigated for HES with modest success. We report a young patient with HES who developed stroke and remained refractory to conventional therapy. Therapy with imatinib mesylate, a selective tyrosine kinase inhibitor that is highly effective in treating patients with BCR-ABL-positive chronic myeloid leukemia, was tried with the patient. The result was impressive, with hematologic remission achieved rapidly. Our finding concurs with recent reports that imatinib mesylate may be a promising agent in the treatment of some cases of HES.
Assuntos
Texto completo: 1 Índice: IMSEAR Assunto principal: Piperazinas / Pirimidinas / Proteínas Tirosina Quinases / Humanos / Masculino / Síndrome Hipereosinofílica / Adulto / Inibidores Enzimáticos Idioma: En Ano de publicação: 2006 Tipo de documento: Article
Texto completo: 1 Índice: IMSEAR Assunto principal: Piperazinas / Pirimidinas / Proteínas Tirosina Quinases / Humanos / Masculino / Síndrome Hipereosinofílica / Adulto / Inibidores Enzimáticos Idioma: En Ano de publicação: 2006 Tipo de documento: Article